Scientists track patients for 15 years after revolutionary cancer cell therapy
NCT ID NCT06985576
Summary
This study aims to monitor the long-term safety and persistence of a CAR-T cell therapy called GF-CART01 for up to 15 years. It will follow 18 patients who previously received this treatment for aggressive B-cell lymphomas that have returned or not responded to other therapies. The main goal is to track any serious side effects and see how long the modified immune cells remain active in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.